BR9608505A - Terapia de combinação dos antagonistas espironolactona e angiotensina ii para o tratamento de insuficiència cardíaca congestiva - Google Patents

Terapia de combinação dos antagonistas espironolactona e angiotensina ii para o tratamento de insuficiència cardíaca congestiva

Info

Publication number: BR9608505A
Authority: BR; Brazil
Prior art keywords: angiotensin; receptor antagonist; spironolactone; combination therapy; treatment
Prior art date: 1995-06-07

Application number

BR9608505A

Other languages

English (en)

Portuguese (pt)

Inventor

Todd E Maclaughlan

Joseph R Schuh

Original Assignee

G D Searle E Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-07

Filing date

1996-06-05

Publication date

1999-07-06

1996-06-05 Application filed by G D Searle E Co filed Critical G D Searle E Co

1999-07-06 Publication of BR9608505A publication Critical patent/BR9608505A/pt

Links

239000002333 angiotensin II receptor antagonist Substances 0.000 title abstract 4
238000002648 combination therapy Methods 0.000 title abstract 3
229960002256 spironolactone Drugs 0.000 title abstract 3
LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 title abstract 3
206010007559 Cardiac failure congestive Diseases 0.000 title abstract 2
206010019280 Heart failures Diseases 0.000 title abstract 2
229940123413 Angiotensin II antagonist Drugs 0.000 title 1
102000003979 Mineralocorticoid Receptors Human genes 0.000 abstract 3
108090000375 Mineralocorticoid Receptors Proteins 0.000 abstract 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 3
229940044551 receptor antagonist Drugs 0.000 abstract 3
239000002464 receptor antagonist Substances 0.000 abstract 3
229940126317 angiotensin II receptor antagonist Drugs 0.000 abstract 2
KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 abstract 1
-1 3,5-dibutyl-1H-1,2,4-triazol-1-yl Chemical group 0.000 abstract 1
206010003445 Ascites Diseases 0.000 abstract 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
206010016654 Fibrosis Diseases 0.000 abstract 1
206010020772 Hypertension Diseases 0.000 abstract 1
230000007882 cirrhosis Effects 0.000 abstract 1
208000019425 cirrhosis of liver Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
125000004076 pyridyl group Chemical group 0.000 abstract 1
125000001425 triazolyl group Chemical group 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)
Peptides Or Proteins (AREA)

BR9608505A 1995-06-07 1996-06-05 Terapia de combinação dos antagonistas espironolactona e angiotensina ii para o tratamento de insuficiència cardíaca congestiva BR9608505A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US48608995A	1995-06-07	1995-06-07
PCT/US1996/009342 WO1996040258A2 (en)	1995-06-07	1996-06-05	Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure

Publications (1)

Publication Number	Publication Date
BR9608505A true BR9608505A (pt)	1999-07-06

Family

ID=23930539

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9608505A BR9608505A (pt)	1995-06-07	1996-06-05	Terapia de combinação dos antagonistas espironolactona e angiotensina ii para o tratamento de insuficiència cardíaca congestiva

Country Status (16)

Country	Link
US (1)	US20040102423A1 (2)
EP (1)	EP0831911B1 (2)
JP (1)	JPH11509838A (2)
KR (1)	KR19990022723A (2)
CN (1)	CN1192696A (2)
AT (1)	ATE216261T1 (2)
AU (1)	AU6158096A (2)
BR (1)	BR9608505A (2)
CA (1)	CA2224222A1 (2)
CZ (1)	CZ291268B6 (2)
DE (1)	DE69620756T2 (2)
DK (1)	DK0831911T3 (2)
ES (1)	ES2175098T3 (2)
IL (1)	IL122246A (2)
PT (1)	PT831911E (2)
WO (1)	WO1996040258A2 (2)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6306826B1 (en)	1997-06-04	2001-10-23	The Regents Of The University Of California	Treatment of heart failure with growth hormone
US6211217B1 (en)	1999-03-16	2001-04-03	Novartis Ag	Method for reducing pericardial fibrosis and adhesion formation
PL353199A1 (en)	1999-08-30	2003-11-03	Aventis Pharma Deutschland Gmbh	Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
CA2400124C (en) *	2000-02-18	2010-12-14	Kazuaki Ikeya	Tnf-.alpha. inhibitors
US7482366B2 (en)	2001-12-21	2009-01-27	X-Ceptor Therapeutics, Inc.	Modulators of LXR
WO2003059884A1 (en)	2001-12-21	2003-07-24	X-Ceptor Therapeutics, Inc.	Modulators of lxr
DE10335027A1 (de) *	2003-07-31	2005-02-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von Angiotensin II Rezeptor Antagonisten
CA2520763A1 (en)	2003-04-03	2004-10-21	The Regents Of The University Of California	Improved inhibitors for the soluble epoxide hydrolase
EP1765311A4 (en)	2004-03-16	2009-04-29	Univ California	REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
US7662910B2 (en)	2004-10-20	2010-02-16	The Regents Of The University Of California	Inhibitors for the soluble epoxide hydrolase
US9512125B2 (en) *	2004-11-19	2016-12-06	The Regents Of The University Of California	Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
WO2007114926A2 (en)	2006-04-04	2007-10-11	The Regents Of The University Of California	Kinase antagonists
WO2008021666A2 (en) *	2006-08-18	2008-02-21	Morton Grove Pharmaceuticals, Inc.	Stable liquid levetiracetam compositions and methods
GB2467670B (en)	2007-10-04	2012-08-01	Intellikine Inc	Chemical entities and therapeutic uses thereof
EP3613743B1 (en)	2008-01-04	2022-03-16	Intellikine, LLC	Processes for the preparation of 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8993580B2 (en)	2008-03-14	2015-03-31	Intellikine Llc	Benzothiazole kinase inhibitors and methods of use
US8637542B2 (en) *	2008-03-14	2014-01-28	Intellikine, Inc.	Kinase inhibitors and methods of use
JP5788316B2 (ja) *	2008-07-08	2015-09-30	インテリカイン，エルエルシー	キナーゼインヒビターおよび使用方法
US20110224223A1 (en) *	2008-07-08	2011-09-15	The Regents Of The University Of California, A California Corporation	MTOR Modulators and Uses Thereof
US8703778B2 (en)	2008-09-26	2014-04-22	Intellikine Llc	Heterocyclic kinase inhibitors
WO2010045542A2 (en)	2008-10-16	2010-04-22	The Regents Of The University Of California	Fused ring heteroaryl kinase inhibitors
US8476431B2 (en)	2008-11-03	2013-07-02	Itellikine LLC	Benzoxazole kinase inhibitors and methods of use
UY32409A (es)	2009-01-30	2010-08-31	Takeda Pharmaceutical	Compuesto de anillo fusionado y su uso
EP2427195B1 (en)	2009-05-07	2019-05-01	Intellikine, LLC	Heterocyclic compounds and uses thereof
US8980899B2 (en)	2009-10-16	2015-03-17	The Regents Of The University Of California	Methods of inhibiting Ire1
CA2799579A1 (en)	2010-05-21	2011-11-24	Intellikine, Inc.	Chemical compounds, compositions and methods for kinase modulation
JP2013545749A (ja)	2010-11-10	2013-12-26	インフィニティーファーマシューティカルズ，インコーポレイテッド	複素環化合物及びその使用
TWI674262B (zh)	2011-01-10	2019-10-11	美商英菲尼提製藥股份有限公司	製備異喹啉酮之方法及異喹啉酮之固體形式
CN103476410B (zh) *	2011-01-11	2020-02-21	戴麦里克斯生物科学有限公司	联合疗法
US9295673B2 (en)	2011-02-23	2016-03-29	Intellikine Llc	Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
CN102816126A (zh) *	2011-06-07	2012-12-12	中国药科大学	具有心血管活性的胺磺酰芳基取代的三氮唑类衍生物、其制备方法及用途
WO2013012915A1 (en)	2011-07-19	2013-01-24	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
MX2014000648A (es)	2011-07-19	2014-09-25	Infinity Pharmaceuticals Inc	Compuestos heterociclicos y sus usos.
KR20140075693A (ko)	2011-08-29	2014-06-19	인피니티 파마슈티칼스, 인코포레이티드	헤테로사이클릭 화합물 및 그의 용도
MX370814B (es)	2011-09-02	2020-01-08	Univ California	Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
MX2015003874A (es)	2012-09-26	2015-12-16	Univ California	Modulacion de ire1.
EP2914296B2 (en)	2012-11-01	2021-09-29	Infinity Pharmaceuticals, Inc.	Treatment of cancers using pi3 kinase isoform modulators
US9481667B2 (en)	2013-03-15	2016-11-01	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2015051241A1 (en)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
MX2021012208A (es)	2013-10-04	2023-01-19	Infinity Pharmaceuticals Inc	Compuestos heterocíclicos y usos de los mismos.
NZ724368A (en)	2014-03-19	2023-07-28	Infinity Pharmaceuticals Inc	Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160975A2 (en)	2014-04-16	2015-10-22	Infinity Pharmaceuticals, Inc.	Combination therapies
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US10350223B2 (en)	2015-03-03	2019-07-16	Richard W. Yee	Compositions and methods for treating ocular diseases
EP4585268A3 (en)	2015-09-14	2025-10-15	Twelve Therapeutics, Inc.	Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US10759806B2 (en)	2016-03-17	2020-09-01	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en)	2016-06-08	2017-12-14	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
RU2754507C2 (ru)	2016-06-24	2021-09-02	Инфинити Фармасьютикалз, Инк.	Комбинированная терапия
AR108906A1 (es)	2016-06-29	2018-10-10	Bristol Myers Squibb Co	Heterociclos de biarilmetilo
WO2020113094A1 (en)	2018-11-30	2020-06-04	Nuvation Bio Inc.	Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3257390A (en) *	1963-06-12	1966-06-21	Merck & Co Inc	Ring a unsaturated 21-hydroxy-3-oxo-17alpha-pregnane-17-carboxylic acid lactone diuretic agents
DE2652761C2 (de) *	1976-11-16	1985-11-21	Schering AG, 1000 Berlin und 4709 Bergkamen	15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3506100A1 (de) *	1985-02-18	1986-08-21	Schering AG, 1000 Berlin und 4709 Bergkamen	1(alpha).7(alpha)-dithiosubstituierte spirolactone, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
CA2075627A1 (en) *	1990-02-13	1991-08-14	William J. Greenlee	Angiotensin ii antagonists incorporating a substituted benzyl element
WO1991015206A1 (en) *	1990-04-05	1991-10-17	E.I. Du Pont De Nemours And Company	Treatment of glaucoma and ocular hypertension with imidazole angiotensin-ii receptor antagonists
CA2053148A1 (en) *	1990-10-16	1992-04-17	Karnail Atwal	Dihydropyrimidine derivatives
US5049565A (en) *	1990-12-07	1991-09-17	Merck & Co., Inc.	Microbial transformation process for preparing anti-hypertensive products
JP3290657B2 (ja) *	1991-05-01	2002-06-10	メルクエンドカムパニーインコーポレーテッド	アンギオテンシンｉｉ拮抗剤として活性な酸性アラルキルトリアゾール誘導体
US5529992A (en) *	1992-04-21	1996-06-25	Curators Of The University Of Missouri	Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
US5264447A (en) *	1992-09-01	1993-11-23	Merck & Co., Inc.	Angiotensin II antagonist
AU5449194A (en) *	1992-10-26	1994-05-24	Merck & Co., Inc.	Combinations of angiotensin-ii receptor antagonists and diuretics
CA2125251C (en) *	1993-06-07	2005-04-26	Yoshiyuki Inada	A pharmaceutical composition for angiotensin ii-mediated diseases

1996
- 1996-06-05 WO PCT/US1996/009342 patent/WO1996040258A2/en not_active Ceased
- 1996-06-05 CZ CZ19973848A patent/CZ291268B6/cs not_active IP Right Cessation
- 1996-06-05 KR KR1019970709165A patent/KR19990022723A/ko not_active Ceased
- 1996-06-05 AT AT96919173T patent/ATE216261T1/de not_active IP Right Cessation
- 1996-06-05 BR BR9608505A patent/BR9608505A/pt not_active Application Discontinuation
- 1996-06-05 JP JP9501683A patent/JPH11509838A/ja not_active Abandoned
- 1996-06-05 ES ES96919173T patent/ES2175098T3/es not_active Expired - Lifetime
- 1996-06-05 CN CN96196086A patent/CN1192696A/zh active Pending
- 1996-06-05 CA CA002224222A patent/CA2224222A1/en not_active Abandoned
- 1996-06-05 EP EP96919173A patent/EP0831911B1/en not_active Expired - Lifetime
- 1996-06-05 DE DE69620756T patent/DE69620756T2/de not_active Expired - Fee Related
- 1996-06-05 IL IL12224696A patent/IL122246A/en not_active IP Right Cessation
- 1996-06-05 AU AU61580/96A patent/AU6158096A/en not_active Abandoned
- 1996-06-05 DK DK96919173T patent/DK0831911T3/da active
- 1996-06-05 PT PT96919173T patent/PT831911E/pt unknown
2002
- 2002-10-15 US US10/271,362 patent/US20040102423A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL122246A (en)	2004-06-01
DE69620756T2 (de)	2002-11-14
KR19990022723A (ko)	1999-03-25
EP0831911B1 (en)	2002-04-17
CN1192696A (zh)	1998-09-09
DK0831911T3 (da)	2002-07-22
WO1996040258A2 (en)	1996-12-19
PT831911E (pt)	2002-09-30
ATE216261T1 (de)	2002-05-15
IL122246A0 (en)	1998-04-05
EP0831911A2 (en)	1998-04-01
CZ384897A3 (cs)	1998-05-13
US20040102423A1 (en)	2004-05-27
WO1996040258A3 (en)	1997-01-23
DE69620756D1 (de)	2002-05-23
CA2224222A1 (en)	1996-12-19
ES2175098T3 (es)	2002-11-16
AU6158096A (en)	1996-12-30
CZ291268B6 (cs)	2003-01-15
JPH11509838A (ja)	1999-08-31

Legal Events

Date	Code	Title	Description
2005-11-08	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2006-07-04	B11B	Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements

Publication	Publication Date	Title
BR9608505A (pt)	1999-07-06	Terapia de combinação dos antagonistas espironolactona e angiotensina ii para o tratamento de insuficiència cardíaca congestiva
WO1996040255A3 (en)	1997-01-23	Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist
NO975741L (no)	1998-01-29	Epoksy-steroidalaldosteronantagonist og antiotensin-II-antagonistkombinasjonsterapi for behandling av kongestiv hjertesvikt
IE902139L (en)	1990-12-14	Imidazolyl alkenoic acids
DE69007740D1 (de)	1994-05-05	Substituierte 5-[(Tetrazolyl)alkenyl]-Imidazole.
NZ330889A (en)	2000-03-27	Cycloalkyl substituted imidazoles and their use in treating CSB/RK/p38 kinase mediated diseases
EP0437103A3 (en)	1991-07-24	Substituted 5-(alkyl)carboxamide imidazoles
IE902140L (en)	1990-12-14	Imidazolyl alkenoic acids
NO2005009I1 (no)	2005-04-18	Emselex-Darifenacin-IUPAC-nabn: (S)-2-(1-Ä2-(2,3-dihydrobenzofuran-5-yl)etylÜ3-pyrrolidinylÜ-2,2-difenylacetamid
EP1045636A4 (en)	2003-09-10	PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR DAMAGED MYOCARD TISSUE
MY110205A (en)	1998-02-28	Imidazolyl-alkenoic acids.
PT85312A (en)	1987-08-01	Process for the preparation of angiotension ii receptor blocking imidazoles and of pharmaceutical
WO2002009760A3 (en)	2003-01-23	Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
AU6564990A (en)	1991-05-09	Substituted n-(imidazolyl)alkyl alanine derivatives
EP0726072A3 (en)	1997-12-17	Composition for the treatment of hypertension and congestive heart failure, containing an angiotensin II antagonist and an endopeptidase inhibitor
AU8534291A (en)	1992-03-02	Renal-selective angiotensin ii antagonists for treatment of hypertension
ES2105939A1 (es)	1997-10-16	Nuevos pirazoles con actividad antagonista de la angiotensina ii.
AU3635793A (en)	1993-09-13	Pyrazolopyrimidin derivatives as angiotensin II receptor antagonists
MX9709976A (es)	1998-03-31	Terapia de combinacion con espironolactona y antagonista de angiotensina ii para el tratamiento de fallas cardiacas congestivas.
MY118704A (en)	2005-01-31	Process for preparation of eprosartan
MX9709978A (es)	1998-03-31	Terapia de combinacion de antagonista de aldosterona epoxi-esteroidal y antagonista de angiotensina ii para tratamiento de insuficiencia cardiaca congestiva.
HUP0101549A3 (en)	2003-07-28	Form vi cristallyc form of 5,6-dichloro-2-(isopropylamino)-1-(betha-l-ribofuranosyl)-1h-benzimidazole
NZ504898A (en)	2002-11-26	(e)-3-[1-n-butyl-5-[2-(2-carboxyphenyl)methoxy-4-chlorophenyl]-1h-pyrazol-4-yl]-2-[(5-methoxy-2,3-dihydrobenzofuran-6-yl)methyl]-prop-2-enoic acid monoargininyl salt as an endothelin receptor antagonist
MY108525A (en)	1996-10-31	Substituted imidazoles.